Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT00569985
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00559104
- Locations
- 🇺🇸
Good Samaritan Regional Medical Center, Phoenix, Arizona, United States
🇺🇸City of Hope National Medical Center--Main Campus, Duarte, California, United States
High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00544570
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT00536601
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00536978
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT00525590
- Locations
- 🇺🇸
University of Arizona / University Medical Center, Tucson, Arizona, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Weill Medical College Department of Neurological Surgery, New York, New York, United States
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00521014
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00505921
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2011-02-15
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 399
- Registration Number
- NCT00499018
- Locations
- 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
- Conditions
- Interventions
- Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)Procedure: Total lymphoid irradiation (TLI)Drug: RituximabDrug: CarmustineDrug: EtoposideDrug: FilgrastimDrug: Anti-thymocyte globulin (ATG)Drug: CyclosporineDrug: Mycophenolate mofetil (MMF)Drug: CyclophosphamideDrug: AcetaminophenDrug: DiphenhydramineDrug: HydrocortisoneDrug: Methylprednisolone
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 3
- Registration Number
- NCT00482053
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.